QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
MWN-AI** Summary
Hagens Berman, a national shareholder rights law firm, has intensified its investigation into uniQure N.V. (NASDAQ: QURE) following substantial rebukes from the FDA regarding the company’s lead gene therapy candidate, AMT-130. The firm is representing investors who acquired uniQure shares between September 24 and October 31, 2025, as part of a securities class action lawsuit, with a crucial deadline for lead plaintiff applications set for April 13, 2026.
The investigation prompted by media reports reveals serious criticisms from FDA officials, which include allegations of data manipulation and misleading comparisons in uniQure's clinical studies. During a press call, an FDA representative referred to AMT-130 as a “failed therapy,” disputing the company's claims about the necessity of sham surgeries in its clinical trials and indicating that the agency never approved the comparisons uniQure purportedly relied on.
Key points of concern highlighted include the FDA's denial of a previously claimed agreement with uniQure regarding surgery protocols and a non-approval of utilizing historical data as a primary control in its studies. Following a lack of clarity about its timelines for a Biologics License Application (BLA), stock prices plummeted by 49% once the discrepancies became widely known.
As the lawsuit alleges that uniQure misrepresented its compliance and the status of its therapy in dealings with the FDA throughout the specified Class Period, investors affected by these developments are encouraged to submit their claims. Hagens Berman, known for safeguarding investor rights, emphasizes that those with insider knowledge of uniQure’s operations should consider whistleblowing avenues.
MWN-AI** Analysis
The recent turmoil surrounding uniQure N.V. (NASDAQ: QURE) presents a precarious situation for investors, especially following stern rebukes from the FDA regarding its lead gene therapy candidate, AMT-130. The FDA's allegations of "distorted data" and misinterpretation of study protocols raise significant concerns about the integrity of the company's clinical trials and regulatory communications.
Investors should exercise extreme caution when considering QURE stock in light of these revelations. The FDA's strong criticism has led to a securities class action lawsuit, indicating a potential for substantial financial liabilities if the allegations are proven true. Given that the stock dropped significantly upon this news, further volatility is likely as the case unfolds.
Potential investors should focus on a few critical factors:
1. **Regulatory Uncertainty**: The FDA's remarks underline a clear disconnect between uniQure and the regulatory body's expectations. With potential re-evaluation of AMT-130’s clinical strategy, the future success of the therapy, and consequently the firm's stock, remains in jeopardy.
2. **Class Action Risks**: The ongoing securities litigation poses financial risks that could further impact investor sentiment. The April 13, 2026, deadline for lead plaintiff applications could catalyze news flow that drives the stock price’s volatility.
3. **Market Sentiment and Recovery Potential**: Consider the amount of time the stock may take to recover from the current negative sentiment. Unless clear, remedial actions are taken by uniQure to regain credibility, a cautious approach would be wise.
In summary, the current landscape for uniQure is laden with risk. Investors are advised to either adopt a wait-and-see approach or consider diversified positions to mitigate exposure until a clearer regulatory path emerges. Further developments regarding leadership transparency and FDA relations will be crucial in evaluating the stock’s future trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit
SAN FRANCISCO, March 18, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.
SUBMIT YOUR QURE LOSSES TO HBSS NOW
The FDA Clash: "A Distorted or Manipulated Comparison"
On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.
The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the mind of FDA" instead of running a correct clinical study.
Key revelations from the March 6 disclosure include:
- Sham Surgery Mischaracterization: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, accusing the company of mischaracterizing the agency's request. The official clarified that the FDA did not ask to "drill holes in skulls," but rather required "one to three nicks in the scalp" under minimal anesthesia.
- Denial of Prior Agreement: While uniQure CEO Matt Kapusta described the sham surgery requirement as a "drastic change" from previous guidance, the FDA official pushed back, stating the agency "never agreed to accept this distorted comparison" using natural history as a comparator.
- Ineligibility for "Plausible Mechanism" Pathway: The official disputed AMT-130's eligibility for streamlined rare-disease pathways, noting it is not an individualized treatment.
The recent reports follow the filing of a securities class action suit.
Investors in uniQure (QURE) are encouraged to visit the Hagens Berman QURE Case Page to review the allegations in the pending litigation: www.hbsslaw.com/cases/uniqure
"The pending securities class action alleges a consistent pattern: that uniQure misrepresented its interactions with the FDA and used a pivotal study design that it knew the agency had not approved," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claim in the pending litigation.
Summary of QURE Class Action Allegations: The "Pivotal" Study Mirage
The securities class action, Scocco v. uniQure N.V., et al. (S.D.N.Y.), alleges that throughout the Class Period (Sept. 24, 2025 – Oct. 31, 2025), defendants failed to disclose:
- No Regulatory Consensus: That the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130.
- Hidden Requirements: That uniQure downplayed the necessity of a sham-controlled surgery arm for Phase III—a requirement the FDA now claims was never waived.
- Timeline Deception: That defendants misled investors regarding the timing of a Biologics License Application (BLA), which was rendered "unclear" once the lack of FDA agreement was revealed on November 3, 2025, sending the stock down 49%.
Critical Deadline: April 21, 2026
If you purchased uniQure ordinary shares during the Class Period (Sept. 24, 2025 – Oct. 31, 2025) and suffered losses, you have until April 13, 2026, to ask the Court to appoint you as Lead Plaintiff.
- Submit Your QURE Losses to HBSS Now
- Contact: Reed Kathrein at 844-916-0895 or email QURE@hbsslaw.com
If you'd like more information and answers to additional frequently asked questions about the uniQure case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding uniQure should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email QURE@hbslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SOURCE Hagens Berman Sobol Shapiro LLP
FAQ**
How might the allegations regarding "distorted" data impact the future regulatory approval process for uniQure N.V. (QURE) and its lead therapy candidate AMT-130?
2. What steps is uniQure N.V. (QURE) taking in response to the FDA's rebuke regarding the sham surgery mischaracterization and the alleged lack of prior agreement on the clinical study design?
3. How could the pending securities class action lawsuit affect investor sentiment and the stock performance of uniQure N.V. (QURE) moving forward?
4. What are the potential implications for uniQure N.V. (QURE) if the FDA continues to deny the eligibility of AMT-130 for streamlined rare-disease pathways, as claimed in the recent reports?
**MWN-AI FAQ is based on asking OpenAI questions about uniQure N.V. (NASDAQ: QURE).
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
